Stocks

Beam Therapeutics BEAM

Health care sectorNasdaq

What to see in Beam Therapeutics now

Is Wall Street adding or cutting?+24

277 13F filers hold it · +24 against the quarter before · shares held +1.0%

Holdings of 06/30
Who bought more than 5%?9.9%

ARK Investment Management holds 9.95% · −2.3pp on the report before

Filed 08/14
What comes next?10/15 (Thu)

10/15 estimated earnings

Due 10/15
Close
$24.44
09/30 close
Day change
−0.3%
vs previous close
Volume
74,700
−12.4% vs 30-day average
52-week range
$20.23$37.98
1-year return
+0.3%
vs the close a year ago
Market cap
$2.5B
103,287,665 shares · reported 07/28

Company

Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Headquarters
Cambridge, Massachusetts
Fiscal year end
12/31
Next earnings
10/15, estimated
  • 10/15 estimated earningsDue 10/15
Exchange
Nasdaq
Headquarters
Massachusetts
SIC code
Biological Products, (No Diagnostic Substances)
Fiscal year end
12/31
CEO pay (proxy)
$5.8M · year ended 25/12/31
CEO pay actually paid
$8.4M · year ended 25/12/31
Next earnings (estimated)
10/15
Last earnings filing
08/04
Korean holdings rank
Outside the top 50
Off-exchange short share, latest day
66.2%
Short share, 20 trading days
66.2% · 1 days, thin sample
Short share, 60 trading days
66.2% · 1 days, thin sample

FINRA daily short volume of off-exchange trades, tallied 10/01. It is not the short interest.

The next earnings day is estimated from the spacing of the last four quarters' 8-K filings.

Korea Securities Depository · released 09/22

Corporate actions

Price

$24.44Day −0.3%1 year +0.3%

26-week trading